Magazine article Drug Topics

Two New Uses Boost Prospects for Schering's Allergy Drug

Magazine article Drug Topics

Two New Uses Boost Prospects for Schering's Allergy Drug

Article excerpt

Physicians who are still on the fence about ordering Clarinex (desloratadine)-or some other nonsedating antihistamine-have two new reasons for choosing the former. The ScheringPlough product, which has been out of the hangar only since the middle of January, has now won approval for two additional indications.

First approved for treating seasonal allergic rhinitis or outdoor allergens, such as pollen, desloratadine can now be used to relieve perennial allergic rhinitis, which is associated with such triggers as dust mites and animal dander, and chronic idiopathic urticaria, or hives, in adults and children 12 years and older. The company claims that the expanded labeling gives desloratadine bragging rights to being the first and only nonsedating antihistamine cleared for use with both indoor and outdoor allergens.

Desloratadine has several other things going for it. Its new labeling states that patients can drink grapefruit juice without fearing that it will affect bioavailability of the drug, and Schering maintains that desloratadine is the first antihistamine that can lay claim to this wording. In addition, broadened labeling states that the drug can be used for patients with both seasonal allergies and mild to moderate asthma. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.